Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial ...
Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform ...
Gifts left in wills in the past are helping to shape the cancer research making a difference to patients today.
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically ...
Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors, today announced the appointment of Lisa ...
It's the latest in a long-running dispute over the drugs, which some view as groundbreaking, while others say they leave much ...
For Britain's 16 million hay fever sufferers, the start of the season promises weeks, if not months, of misery. But could ...
April 2026 Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Third positive pivotal Phase III clinical trial of AstraZeneca's IL-33-targeting biologic further demonstra ...
LC: Manufacturability is the field's most critical near-term challenge, especially for ex vivo cell therapies. Encouragingly, ...
Strategic collaboration with a leading global CRO supports disciplined trial execution and operational efficiency, advancing Faron's mission to provide treatment for patients with HR-MDS TURKU, FI / ...
In a busy household, “some nights everyone just needs something quick and easy,” said Dr. Alicia Tucker, attending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results